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Abstract
Background: Patients on haemodialysis (HD) are at an increased risk of sustaining thrombotic events especially to
their vascular access which is essential for maintenance of HD.
Objectives: To assess whether 1) markers of coagulation, fibrinolysis or endothelial activation are increased in
patients on HD compared to controls and 2) if measurement of any of these factors could help to identify patients at
increased risk of arteriovenous (AVF) access occlusion.
Patients/Methods: Venous blood samples were taken from 70 patients immediately before a session of HD and
from 78 resting healthy volunteers. Thrombin-antithrombin (TAT), D-dimer, von Willebrand factor (vWF), plasminogen
activator inhibitor-1 antigen (PAI-1) and soluble p-selectin were measured by ELISA. C-reactive protein (hsCRP) was
measured by an immunonephelometric kinetic assay. Determination of the patency of the AVF was based upon
international standards and was prospectively followed up for a minimum of four years or until the AVF was non-
functioning.
Results: A total of 70 patients were studied with a median follow-up of 740 days (range 72-1788 days). TAT, D-
dimer, vWF, p-selectin and hsCRP were elevated in patients on HD compared with controls. At one year follow-up,
primary patency was 66% (46 patients). In multivariate analysis TAT was inversely associated with primary assisted
patency (r= -0.250, p= 0.044) and secondary patency (r = -0.267, p= 0.031).
Conclusions: The novel finding of this study is that in patients on haemodialysis, TAT levels were increased and
inversely correlated with primary assisted patency and secondary patency. Further evaluation is required into the
possible role of TAT as a biomarker of AVF occlusion.
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Introduction
Acute thrombosis of vascular access (VA) accounts for
20-25% of all hospitalisations of haemodialysis (HD) patients
[1,2] which leads to considerable morbidity and cost to
healthcare providers [3,4]. Coagulation activation has been
implicated in the increased incidence of acute thrombotic
events observed in patients on HD. Despite the use of heparin,
or low molecular-weight heparins, a steady increase in
thrombin generation has been shown to occur during HD [5–7].
In addition increased levels of fibrinogen and prothrombin
fragment F1 + 2 (which reflects thrombin generation) have
been found in patients on HD compared with controls [8,9].
Thrombin-antithrombin complex (TAT) is a sensitive marker
of intravascular thrombin generation indicating activation of
coagulation. Plasma levels in samples from both the VA and
the systemic venous circulation are increased during dialysis
and remain elevated up to 48 hours post-dialysis in patients
[6,10]. In a small study TAT levels were found to be increased
in patients on HD [11]. D-dimer is a degradation product
formed when plasmin acts on cross-linked fibrin, and may
reflect increased deposition of intra-vascular cross-linked fibrin,
and/or up regulation of the fibrinolytic pathway. Increases in
baseline D-dimer levels in patients on HD compared to healthy
controls have been demonstrated and these levels have been
shown to increase further immediately following dialysis
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[10,12]. Furthermore D-dimer levels are independently
associated with the presence of ischaemic heart disease in HD
patients [12,13].
While markers of the coagulation pathway have been shown
to be increased both at the VA site and also in the systemic
circulation [14] it is unclear whether there is an accompanying
upregulation of the fibrinolytic pathway. Increased levels of
tissue plasminogen activator (t-PA) have been demonstrated at
the VA site, but not in the systemic circulation [15]. Erdem et al
found no difference in t-PA levels between venous samples
taken from healthy controls and HD patients [11]. Plasmin-
antiplasmin complexes, and plasminogen activator inhibitor 1
(PAI-1) have been shown to be either increased or unchanged
in patients on HD compared to controls [11,12,16–19].
Relatively few large studies have analysed both markers of the
coagulation and fibrinolytic pathway, together in patients on HD
compared to healthy controls and this area merits further
investigation.
Endothelial dysfunction which has been shown to occur in
patients on HD may also contribute to thrombotic events
[20,21]. To date, there has been only been a limited number of
prospective studies which have assessed the potential
relationship between coagulation and/or endothelial biomarkers
and VA patency outcomes. These have been limited by the
inclusion of composite endpoints such as deep vein thrombosis
and coronary events [22]. It is currently unknown if measuring
cardiovascular biomarkers may help identify patients who are
at increased risk of VA occlusion.
In this prospective study we aim to compare markers of
coagulation, fibrinolysis and endothelial function in patients on
HD compared to healthy controls and determine their
relationship to arteriovenous-fistula (AVF) patency rates.
Patients and Methods
Seventy consecutive patients on HD and 78 healthy
volunteers were recruited into this observational comparative
study over a 15 month period (Table 1). Patients were eligible
for inclusion if they were established on HD and between 20 to
80 years of age. Patients were excluded if they had a history of
haematological malignancy, a known bleeding diathesis or
coagulopathy or concomitant warfarin therapy. Our definitions
of patency are those recommended by the Society of Vascular
Surgery and American Association for Vascular Surgery [23].
Primary patency is defined as uninterrupted patency without
endovascular or surgical intervention being performed on the
fistula. It is the interval from the time of access placement until
any intervention designed to maintain or re-establish patency.
Primary-assisted patency is defined as patency which is
maintained by endovascular or surgical intervention. It is the
interval from the time of access placement until measurement
of patency. The secondary patency rate is defined as the time
from formation of the fistula until the fistula is occluded or
abandoned. Patients were followed up for a minimum of four
years if their AVF remained patent or until the end of the
secondary patency of the AVF.
Healthy control subjects had no history or clinical signs of
renal, cardiac, cerebrovascular or vascular disease.
Ethics Statement
Full ethical approval for the study was granted by the
Grampian Research Ethics Committee. Each individual study
participant gave full informed written consent prior to
enrolment.
Sample collection
It has previously been shown that there are differences in
coagulation, fibrinolysis and platelet biomarkers between
simultaneous samples in a single patient taken from the VA
and peripheral veins [15,24]. In this case-control study similar
sites of blood sampling were compared, namely the ante-
cubital vein of fully rested patients in the HD and control group.
A 21-gauge needle was used with a tourniquet applied to the
upper arm. The cuff was removed once the first trickle of blood
appeared in the first sample tube to prevent activation by stasis
and the first 5 ml were discarded. Samples from the HD
patients were taken immediately before the start of a single
dialysis session and prior to administration of heparin.
Unfractionated heparin was used as anticoagulant was used in
all patients although they had not received any heparin for at
least 48 hours. All patients were dialysed on synthetic
Helixone™ membrane (Fresenius Medical Care, Notts,
England) which is a polysulfone membrane. All membranes
were high flux but differed in the surface area (m2) between FX
60 (1.4m2), FX80 (1.8m2) and FX100 (2.1m2). The samples
were centrifuged at 2500 xg for 15 minutes, plasma was then
transferred to a fresh tube and the centrifugation step repeated.
The resulting platelet poor plasma was aliquoted and stored at
below -70 oC.
Table 1. Baseline demographics.
 Controls (n=78) HD-Patients (n=70)
Mean Age (Range) 48.9 (23-77) 59.0 (20-80)*
Sex Ratio (M:F) 28:50 46:24*
Reformed Or Current Smoker
(%) 18 (23) 40 (57)*
Mean BMI kg/m2 (SD) 27.1 (4.78) 25.5Ѱ (4.52)
 Diabetic (%) 12 (17)
 Coronary disease (%) 19 (27)
 Cerebrovascular (%) 4 (6)
 Peripheral Vascular (%) 3 (4)
 Any CV disease (%) 21 (30)
 Aspirin (%) 40 (57)
Clopidogrel (%)  5 (7)
Any Antiplatelet (%)  43 (61)
 Statin therapy (%) 35 (50)
 Erythropoietin therapy (%) 63 (90)
Mean Serum LDL-Cholesterol
mmol/L (SD) 3.06 (0.84) 2.32* (0.76)
* P < 0.001, ѰP< 0.05
CV − Cardiovascular disease, BMI − Body Mass Index, SD − Standard Deviation
TAT and Patency of AVF for Haemodialysis
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Assays
TAT was measured using a commercially available ELISA
(Enzygnost TAT micro, DADE Behring, Marburg GmbH,
Marburg, Germany). The limits of detection were between 2
and 60 µg/l with an intra-assay co-efficient of variation (CV) of
5.7%.
D-dimer was measured using a VIDAS D-Dimer Exclusion
automated quantitative test (bioMérieux, Lyon, France). The
limits of detection were between 45 and 10,000 µg/l with an
inter-assay CV of 3.5%.
PAI-1 antigen was measured using an in-house ELISA [25].
The assay has a limit of 30 ng/l and intra- and inter-assay CV
of 7.2% and 5.5%.
Plasmin-α2antiplasmin was quantified using an in-house
ELISA, as previously described [26].
Von Willebrand factor (vWF) antigen is a well recognised
marker of endothelial dysfunction [26] and was measured by an
in-house ELISA using polyclonal rabbit-antihuman vWF
antibody and horse-radish peroxidise conjugated antibody
(both Dako, Glostrup, Denmark) with an inter-assay CV of
7.8%.
Soluble P-selectin was performed using a commercially
available ELISA kit (Human sP-selectin, BMS219/3CE, Bender
Medsystems, Vienna, Austria). The limits of detection were
between 2.19 and 140 µg/l with an inter-assay CV of 9.6%.
High sensitivity (hs)-CRP was measured using a
commercially available immunonephelometric kinetic assay
(BN ProSpec, Siemens, Tarrytown, USA) using Cardiophase
hsCRP reagents. The limit of detection was 0.100 mg/l with an
inter-assay CV of 3.1% and an intra assay CV between 0.5–
2.1%.
Statistical Analysis
Baseline demographics of HD patients and control subjects
were compared using the Mann–Whitney U test or chi-squared
test as appropriate. Where significant differences existed in the
two groups (Controls to HD patients) multivariate linear
regression analysis was used to adjust these comparisons for
confounding factors which included age, gender, BMI,
dyslipidemia and smoking history differences. Patency rates
were calculated using life table analysis, log rank testing and
Kaplan-Meier techniques. Correlation analysis was performed
with Spearman’s rank coefficient and multivariate linear
regression analysis. Data analysis was performed using SPSS
version 20.0 (SPSS, Chicago, Illinois). A p < 0.05 was
considered significant. Statistical advice for the study was
provided by the Medical Statistics Unit, Department of
Population Health, University of Aberdeen.
Results
Patient characteristics
Patient demographics are shown in Table 1. There was a
higher proportion of males, increased age, increased incidence
of dyslipidaemia, smoking and lower BMI in the HD patient
group compared to controls. The cause of established chronic
kidney disease was: chronic glomerulonephritis (n=20),
diabetes (n=11), polycystic kidney disease (n=8), uncertain
aetiology (n=8), obstructive nephropathy (n=7), renal artery
stenosis/ hypertensive nephropathy (n=5), chronic
pyelonephritis (n=4), congenital abnormalities (n = 3),
Wegeners (n=2), bilateral nephrectomy (n=1), and renal
tuberculosis (n = 1). All patients had been established on HD
for a minimum of two weeks with a mean of 1013 days (Range
18–4370). The mean number of days the AVF had been patent
for prior to sampling was 849 (Range 48–4488).
Haemostatic variables in HD versus controls
A linear multivariate analysis was performed adjusting for
age, gender, dyslipidemia, BMI and smoking history.
Coagulation
TAT complex levels were statistically significantly higher in
patients on HD compared to controls (median [interquartile
range] 4.43 [2.53-6.17] versus 2.84 [1.81-3.82] µg/l p < 0.001)
(Figure 1). TAT levels in patients on antiplatelet therapy were
not statistically significantly different from TAT in patients not
on antiplatelet therapy (median = 4.65 (IQR 2.45-6.31) versus
median = 4.43 (IQR 3.56-5.33), p>0.05).
Similarly, D-dimer levels were statistically significantly higher
in patients on HD compared to controls (819.2 [428.6-1263.7]
versus 265.5 [175.0-401.5] µg/l p < 0.001) (Figure 2).
Fibrinolysis: There was no significant difference between
plasma PAI-1 levels in patients on HD compared to controls
(19.33 [12.23. -30.43] versus 23.22 [17.33-35.04] ng/l, p =
0.089). Plasmin-α2antiplasmin levels were also quantified in
patients on HD and the control group, but in both cases were
below the limit of detection (data not shown).
Endothelial function
vWF antigen (P < 0.001), soluble P-selectin (p < 0.001) and
hsCRP (p < 0.001) were statistically significantly elevated in the
patients on HD compared to controls (Table 2).
Figure 1.  Plasma TAT concentrations in healthy controls
and patients on HD.  TAT was quantified by ELISA and the
results expressed on a box plot showing the median (bars),
minimum and maximum values (whiskers) and interquartile
range (box).
doi: 10.1371/journal.pone.0067799.g001
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Patency Rates
Follow-up.  Median follow-up was 740 days (Range
72-1788). At 1 year follow-up, primary patency was 66% (46
patients), primary assisted patency 74% (52) and secondary
patency 77% (54). Of these, 16 (21%) patients had
interventions to maintain primary patency during follow-up. At a
median follow-up of 740 days, 44% (31 patients) maintained
primary patency, 49% (34) maintained primary assisted
patency and 50% (35) maintained secondary patency. AVF
survival is shown for primary, primary assisted and secondary
patency (Figure 3).
Bivariate analysis.  TAT showed an inverse correlation with
primary patency (r = -0.341, p = 0.004), primary assisted
patency (r = -0.296, p = 0.013) and secondary patency (r =
-0.269, p = 0.024). hsCRP showed an inverse correlation with
secondary patency (r = -0.242, p = 0.043). There were no other
significant correlations with patency.
Multivariate analysis.  The correlations between TAT and
patency remained significant after adjustment for age,
diabetes, smoking, history of cardiovascular disease, and
number of days since AVF creation in a multivariate linear
Figure 2.  Plasma concentration of D-dimer in healthy
controls and patients on HD.  D-dimer was quantified by
ELISA and the results expressed on a box plot showing the
median (bars), minimum and maximum values (whiskers), and
interquartile range (box).
doi: 10.1371/journal.pone.0067799.g002
regression model. There was a trend toward an inverse
relationship between TAT and primary patency (r = -0.238, p =
0.056). TAT was significantly inversely associated with primary
assisted patency (r = -0.250, p = 0.044) and secondary patency
(r = -0.267, p = 0.031). HsCRP no longer remained significantly
associated with patency rates after adjustment.
Discussion
This study has shown the existence of a procoagulant state
in patients with established chronic kidney disease receiving
HD, with increased levels of TAT and D-dimer compared to
healthy controls. In contrast to previous studies we were
unable to detect a significant difference in PAI-1 antigen levels
in patients on HD compared to controls [17]. Previous studies
have shown no differences in the levels of tissue plasminogen
activator (t-PA) in patients on HD compared to controls [17]. In
line with these findings we found negligible levels of plasmin-α2
antiplasmin complex in both the test and control group,
indicating that plasmin generation was not stimulated in
patients receiving HD. However, the significant increase in
plasma D-dimer associated with patients on HD suggests
ongoing activation of both the coagulation and fibrinolytic
systems. A potential explanation for this finding may be that
unlike D-dimer, plasmin-α2 antiplasmin complex is rapidly
Figure 3.  Cumulative survival analysis of patency for
VA.  The number at risk at each time point is detailed.
doi: 10.1371/journal.pone.0067799.g003







vWF [IU/ml] 0.878 [0.645-1.028] 1.50 [1.09-1.96]*
Hs-CRP [mg/L] 1.36 [0.67-2.69] 4.28 [1.59-8.99]*
Soluble P-selectin [µg/l] 24.7 [13.4-43.3] 40.4 [14.2-88.6]*
*. P < 0.001 vs Controls vWF – Von Willebrand Factor, hs-CRP – high sensitivity
C-Reactive Protein
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cleared from the systemic circulation and would be rapidly
diluted by the high flow rate in the AVF. Therefore there may
be a change in plasmin generation and plasmin-α2 antiplasmin
complex at the fistula site which is reflected as a change in D-
dimer in the systemic circulation.
D-dimer is excreted by the kidney and thus a rise in levels in
patients with ESRD compared to healthy controls would be
expected. Increased levels have also been shown to occur with
advancing age, in patients with heart disease, infection,
trauma, some cancers and in patients with a high rheumatoid
factor [27]. While this suggests that a rise in D-dimer should be
interpreted with caution, in this study the notable feature is that
it occurred in association with a rise in the levels of TAT. We
have confirmed the findings of the one previous small study
which measured TAT in 26 HD patients and 22 healthy controls
[11]. The novel finding of the present study is that TAT levels at
baseline were inversely correlated with primary assisted
patency and secondary patency. TAT is a sensitive marker of
intravascular thrombin generation and to the best of our
knowledge no previous study has looked at the relationship
between TAT and VA patency rates. The utility of TAT
measurement to aid the identification of patients at risk of acute
cardiac events has been noted in studies involving patients
with symptomatic cardiac disease including patients on HD
[28,29]. This further suggests that the assessment of TAT may
have a role in the identification of patients at risk of acute
thrombotic events. The use of novel thrombin inhibitors, such
as dabigatran, is increasing among patients with venous
thromboembolism but also inpatients with atrial fibrillation and
cardiovascular risk factors. In HD patients who are high risk
patients for thrombotic events with raised TAT levels these
drugs may be of potential value to prevent VA thrombosis and
their role should be evaluated in future studies.
A previous study has assessed the relationship between D-
dimer levels and patency rates and like our study showed no
association [30]. However, Stolic et al, noted that plasma levels
of D-dimer increased with time from fistula formation and at 1
year did show a similar level of correlation with patency rates.
De Marchi et al prospectively studied 30 non-diabetic HD
patients for 2 years and noted that PAI-1 and factor VII were
independent predictors of fistula survival [31]. We found no
increase in PAI-1 levels compared to healthy controls, although
it should be noted that only 12 (17%) of patients in our study
had diabetes.
The present study has suggested that alteration in the
endothelial cell surface to a more pro-coagulant and/or
inflammatory state occurs in patients on HD compared to
controls as reflected by increased levels of vWF, P-selectin and
hsCRP. Platelet adhesion to the vascular endothelium at high
shear is mediated by multimeric adhesive vWF and plasma
vWF is an established marker of endothelial activation.
Increased plasma levels of vWF in patients on HD have been
reported in previous studies [32]. Levels of vWF have also
been shown to increase by 0.15 U/ml for every 10 years of age
[33], but after applying this correction factor vWF was still
significantly higher in the patients on HD compared to controls.
However, we found no correlation between baseline vWF
levels and patency rates. Sioulis et al, in a study of 54 HD
patients, found that baseline vWF levels predicted an increased
risk of a composite endpoint of thrombo-embolic events
(including deep venous thrombosis, acute limb ischaemia and
coronary events) at 15 months follow-up, but did not correlate it
with access patency rates [22].
This is the largest study to assess venous samples for
soluble P-selectin in HD patients and we have demonstrated
elevated levels compared with controls. Soluble P-selectin
predominantly reflects platelet activation, although it is also
found in the Weibel-Palade bodies of endothelial cells from
which it can be released upon activation. Thus, in the present
study, the high level of soluble P-selectin in patients on HD
may reflect both platelet and endothelial cell activation and
could contribute to a prothrombotic state. It did not, however,
show any relationship with patency rates.
HsCRP can lead to endothelial activation through induction
of adhesion molecules, chemokines, neutrophil migration and
microinflammation in the AVF [34–36]. CRP levels have also
been shown to increase with age, but the differences observed
between the groups in our study are larger than that which
could be attributed to age alone [37]. We have shown that high
levels of hsCRP are associated with a reduced VA patency
rate, but this was not maintained on multivariate analysis. Chou
et al, in a retrospective study showed a similar relationship [35].
We have previously shown hsCRP to be elevated in the VA of
HD patients compared to simultaneous venous samples which
may be a factor in local acceleration of VA thrombosis [24].
Study Limitations
In order to enable a comparison with a control group it was
necessary to study venous samples in both groups as the
physiological conditions of a fistula cannot be reproduced in
controls. The AVF samples as used in some studies of
coagulation in HD patients are subject to turbulent blood flow
and high shear stresses, which may lead to localised
coagulation activation. We have previously shown that the
levels of TAT, D-dimer, vWF, are similar in samples taken from
vein and VA site, while hsCRP levels were increased in VA
compared to venous samples [24]. The HD group and controls
were not matched in terms of age, sex, BMI, lipid profile and
smoking history and these were adjusted for in a multivariate
linear regression analysis. Blood samples were not taken at the
time of the patients’ fistula formation and the patients had been
on HD for varying lengths of time, although the number of days
since AVF creation was corrected for in the multivariate
analysis. A further limitation was our inclusion of patients on
antiplatelet agents which are known to affect platelet activation
and thrombin generation. A Cochrane review supports the use
of antiplatelet agents to prolong AVF survival [38]. We felt it
would be unethical to limit the study to patients on HD not on
antiplatelet therapy. We were, however, surprised that only
61% of our patients were actually receiving antiplatelet therapy.
Importantly, we found no differences in the levels of TAT in
patients who were or were not on antiplatelet therapy which is
in keeping with the findings of previous studies [39,40].
Conclusions
This study has confirmed the findings of one small previous
study that TAT levels are increased in in the systemic
TAT and Patency of AVF for Haemodialysis
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circulation in patients with established chronic kidney disease
receiving HD. We have shown an increase in fibrin deposition
which may lead to a possible increased incidence of VA
thrombosis. In particular, we have shown for the first time that
levels of plasma TAT were inversely correlated with patency
rates. Further large scale studies which measure TAT levels
following the formation of a new fistula and serially thereafter
are required to assess the role of TAT as a potential biomarker
of vascular access occlusion. These studies would aim to
establish an appropriate cut off value for TAT which would
allow the identification of high risk patients such that
appropriate targeted therapy and surveillance could be
performed.
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